Taysha Gene Therapies, Inc. (TSHA)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Taysha Gene Therapies, Inc. (“Taysha” or “the Company”) (NASDAQ: TSHA). Investors who purchased Taysha securities prior to August 14, 2023, and continue to hold to the present are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Taysha and certain of its officers and/or directors have allegedly engaged in corporate wrongdoing.
What’s Next?
If you are aware of any facts relating to this investigation, or purchased Taysha shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]